Ruth Wilde Joins FetalFirst Advisory Board as Advisor for Family Support & Counselling
Leading UK Fertility Counsellor Brings 25+ Years of Expertise to AI-Powered Prenatal Diagnostics Platform
London, UK – October 23, 2025 – FetalFirst, the AI-powered prenatal diagnostics platform transforming maternal healthcare through real-time anomaly detection, today announces the appointment of Ruth Wilde to its Advisory Board as Advisor for Family Support & Counselling.
Ruth Wilde, one of the UK's most respected counsellors in reproductive medicine, brings over 25 years of leadership experience supporting parents through fertility challenges, pregnancy loss, and complex prenatal diagnoses. Her appointment strengthens FetalFirst's commitment to ensuring that advanced AI diagnostics are delivered with empathy, compassion, and human-centered care.
A Voice for Parents at the Heart of Innovation
"Ruth is one of the most respected counsellors in reproductive medicine—she has spent decades supporting parents through fertility challenges, pregnancy loss, and the hardest decisions anyone can face," said Nina Abide, Founder and CEO of FetalFirst. "Her wisdom around clarity, compassion, and cultural sensitivity already shapes the way we design the FetalFirst journey. We're honored to formalize her role on our Advisory Board."
Ruth's extensive background includes serving as:
Chair of the British Infertility Counselling Association (BICA)
Executive Committee Member of the British Fertility Society (BFS)
Board Member of the Human Fertilisation & Embryology Authority (HFEA)
She was awarded Honorary Membership by both BICA and BFS for her transformative impact on patient care in reproductive medicine.
Bridging AI Diagnostics with Human-Centered Support
FetalFirst's mission is to empower every parent facing a fetal anomaly diagnosis to make informed, autonomous decisions with world-class support. The platform combines real-time AI-powered anomaly detection with a comprehensive parent companion app that provides:
Personalized pregnancy monitoring and roadmap
Patient-friendly educational content about detected anomalies
Global telehealth access to specialist consultants
Support communities for parents navigating complex diagnoses
Intervention concierge services
Connections to global disability-specific advocate organizations and philanthropists
Care coordination from diagnosis through delivery
"Her voice will be pivotal in ensuring that clarity, compassion, and cultural sensitivity remain at the heart of FetalFirst's mission: empowering every parent facing a fetal anomaly to make informed, autonomous decisions with world-class support," added Abide.
Why Ruth Wilde's Expertise Matters
Receiving a prenatal diagnosis of a fetal anomaly is one of the most emotionally challenging experiences expectant parents can face. While FetalFirst's AI technology enables earlier and more accurate detection, Ruth's guidance ensures that parents receive the compassionate, culturally sensitive support they need to process information, explore options, and make decisions aligned with their values.
"With Ruth's guidance, we are strengthening our commitment to a future where advanced AI diagnostics meet empathetic, human-centered care," said Abide.
About FetalFirst
FetalFirst is an AI-powered prenatal diagnostics platform that detects fetal anomalies from ultrasound and genomic data in real-time, enabling early intervention and better outcomes. Built on Google Cloud with edge AI deployment via NVIDIA IGX Orin, FetalFirst combines cutting-edge technology with comprehensive parent support to transform prenatal care from reactive to predictive.
The platform features dual interfaces: a clinician diagnostic tool delivering severity-graded results within seconds, and a parent companion app providing personalized care coordination, educational resources, global telehealth access, and community support.
FetalFirst has secured NHS ethics approval, NHS Data Security & Protection Toolkit certification, and is currently piloting with the EHDS (European Health Data Space) Pathfinder program in Estonia and Finland. The company is a member of the NVIDIA Inception program and is backed by advisors from NHS, Imperial College London, UCL, and Tartu University Hospital.
